share_log

Panbela Therapeutics | 8-K: Current report

SEC announcement ·  Feb 14 06:35
Summary by Futu AI
On February 7, 2024, Panbela Therapeutics, Inc. reported to the SEC that its Compensation Committee approved retention bonuses for employees, including CEO Jennifer K. Simpson and CFO Susan Horvath. The bonuses are contingent on employment through August 15, 2024, or until a change in control of the company occurs. Simpson and Horvath are set to receive $54,281 and $34,299 respectively. Additionally, the Committee certified the cash incentive compensation for fiscal year 2023, with Horvath receiving $119,394. Despite being eligible for $227,084, Simpson waived her cash incentive for 2023. The retention agreement details were filed with the SEC and are incorporated into the report.
On February 7, 2024, Panbela Therapeutics, Inc. reported to the SEC that its Compensation Committee approved retention bonuses for employees, including CEO Jennifer K. Simpson and CFO Susan Horvath. The bonuses are contingent on employment through August 15, 2024, or until a change in control of the company occurs. Simpson and Horvath are set to receive $54,281 and $34,299 respectively. Additionally, the Committee certified the cash incentive compensation for fiscal year 2023, with Horvath receiving $119,394. Despite being eligible for $227,084, Simpson waived her cash incentive for 2023. The retention agreement details were filed with the SEC and are incorporated into the report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.